From the Department of Neuroradiology (E.P., A.C.), Neurocenter of Southern Switzerland, Lugano, Switzerland
Department of Health Sciences (L.R., M.P.S., L.C.), University of Genova, Genova, Italy.
AJNR Am J Neuroradiol. 2021 Jun;42(6):1061-1068. doi: 10.3174/ajnr.A7082. Epub 2021 Mar 25.
Demyelinating lesions in the anterior visual pathways represent an underestimated marker of disease dissemination in patients with MS. We prospectively investigated whether a dedicated high-resolution MR imaging technique, the 3D-T2-STIR-ZOOMit, improves demyelinating lesion detection compared with the current clinical standard sequence, the 2D-T2-STIR.
3T MR imaging of the anterior visual pathways (optic nerves, chiasm, and tracts) was performed using 3D-T2-STIR-ZOOMit and 2D-T2-STIR, in patients with MS and healthy controls. Two experienced neuroradiologists assessed, independently, demyelinating lesions using both sequences separately. 3D-T2-STIR-ZOOMit scan-rescan reproducibility was tested in 12 patients. The Cohen κ was used for interrater agreement, and the intraclass correlation coefficient for reproducibility. Between-sequence detection differences and the effects of location and previous acute optic neuritis were assessed using a binomial mixed-effects model.
Forty-eight patients with MS with ( = 19) or without ( = 29) past optic neuritis and 19 healthy controls were evaluated. Readers' agreement was strong (3D-T2-STIR-ZOOMit: 0.85; 2D-T2-STIR: 0.90). The 3D-T2-STIR-ZOOMit scan-rescan intraclass correlation coefficient was 0.97 (95% CI, 0.96-0.98; < .001), indicating excellent reproducibility. Overall, 3D-T2-STIR-ZOOMit detected more than twice the demyelinating lesions ( = 89) than 2D-T2-STIR ( = 43) (OR = 2.7; 95% CI, 1.7-4.1; < .001). In the intracranial anterior visual pathway segments, 33 of the 36 demyelinating lesions (91.7%) detected by 3D-T2-STIR-ZOOMit were not disclosed by 2D-T2-STIR. 3D-T2-STIR-ZOOMit increased detection of demyelinating lesion probability by 1.8-fold in patients with past optic neuritis (OR = 1.8; 95% CI, 1.2-3.1; = .01) and 5.9-fold in patients without past optic neuritis (OR = 5.9; 95% CI, 2.5-13.8; < .001). No false-positive demyelinating lesions were detected in healthy controls.
Dedicated 3D-T2-STIR-ZOOMit images improved substantially the detection of MS disease dissemination in the anterior visual pathways, particularly in the intracranial segments and in patients without past optic neuritis.
在前视路中的脱髓鞘病变是多发性硬化症(MS)疾病传播的一个被低估的标志物。我们前瞻性地研究了一种专用的高分辨率磁共振成像技术(3D-T2-STIR-ZOOMit)是否比当前的临床标准序列(2D-T2-STIR)更能提高脱髓鞘病变的检测。
对 MS 患者和健康对照者的前视路(视神经、视交叉和视束)进行了 3T MR 成像,使用了 3D-T2-STIR-ZOOMit 和 2D-T2-STIR。两位有经验的神经放射科医生分别使用这两种序列对脱髓鞘病变进行评估。在 12 名患者中测试了 3D-T2-STIR-ZOOMit 扫描-重扫的可重复性。使用 Cohen κ 评估观察者间的一致性,使用组内相关系数评估可重复性。使用二项混合效应模型评估了序列间检测差异以及位置和既往急性视神经炎的影响。
评估了 48 例有( = 19)或无( = 29)既往视神经炎的 MS 患者和 19 名健康对照者。读者的一致性很强(3D-T2-STIR-ZOOMit:0.85;2D-T2-STIR:0.90)。3D-T2-STIR-ZOOMit 扫描-重扫的组内相关系数为 0.97(95%CI,0.96-0.98; <.001),表明具有极好的可重复性。总体而言,3D-T2-STIR-ZOOMit 检测到的脱髓鞘病变( = 89)是 2D-T2-STIR ( = 43)的两倍多(OR = 2.7;95%CI,1.7-4.1; <.001)。在颅内前视路节段中,3D-T2-STIR-ZOOMit 检测到的 36 个脱髓鞘病变中有 33 个(91.7%)未被 2D-T2-STIR 揭示。在既往有视神经炎的患者中,3D-T2-STIR-ZOOMit 使脱髓鞘病变的检测概率增加了 1.8 倍(OR = 1.8;95%CI,1.2-3.1; =.01),在既往无视神经炎的患者中增加了 5.9 倍(OR = 5.9;95%CI,2.5-13.8; <.001)。在健康对照者中未发现假阳性脱髓鞘病变。
专用的 3D-T2-STIR-ZOOMit 图像显著提高了在前视路中 MS 疾病传播的检测,尤其是在颅内节段和既往无视神经炎的患者中。